Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis

被引:21
作者
de Oliveira, WRP
Carrasco, S
Neto, CF
Rady, P
Tyring, SK
机构
[1] Univ Sao Paulo, Dept Dermatol, Sao Paulo, Brazil
[2] Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77550 USA
[3] Univ Texas, Med Branch, Dept Immunol, Galveston, TX 77550 USA
[4] Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77550 USA
关键词
epidermodysplasia verruciformis; cell-mediated immunity; human papilloma virus; DNCB sensitization; lymphocyte transformation;
D O I
10.1111/j.1346-8138.2003.tb00372.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Epidermodysplasia verruciformis (EV) is a rare disease that usually begins in childhood and is characterized by a generalized infection by human papilloma virus (HPV), frequent associations with cutaneous carcinomas, and abnormalities of cell-mediated immunity (CMI). We studied nonspecific CMI in 13 patients with EV by bacterial skin tests, allergic reactions to dinitrochlorobenzene (DNCB), measurement of responses to phytohemagglutinin (PHA), and quantification of T lymphocytes and T lymphocytes subsets in peripheral blood. Impairment of CMI was manifested by the cutaneous anergy to a variety of common skin antigens and, by the reduction of the lymphocyte transformation to PHA. There were no correlation between the severity of cases and abnormalities of CMI in our patients, however; the impairment of CMI was lower in cases of short duration, suggesting that the impairment of CMI in EV might reflect a long period of disease.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 16 条
[1]  
GLINSKI W, 1981, DERMATOLOGICA, V162, P141
[2]   CELL-MEDIATED-IMMUNITY IN EPIDERMODYSPLASIA VERRUCIFORMIS [J].
GLINSKI, W ;
JABLONSKA, S ;
LANGNER, A ;
OBALEK, S ;
HAFTEK, M ;
PRONIEWSKA, M .
DERMATOLOGICA, 1976, 153 (04) :218-227
[3]  
GUIMARAES NS, 1997, AN BRAS DERMATOL, V772, P583
[4]   SPECIFIC CELL-MEDIATED-IMMUNITY IN PATIENTS WITH EPIDERMODYSPLASIA VERRUCIFORMIS AND PLANE WARTS [J].
HAFTEK, M ;
JABLONSKA, S ;
ORTH, G .
DERMATOLOGICA, 1985, 170 (05) :213-220
[5]  
Jablonska S, 1994, Curr Top Microbiol Immunol, V186, P157
[6]  
JABLONSKA S, 1991, CANC SKIN, P101
[7]  
JABLONSKA S, 2001, HUMAN PAPILLOMAVIRUS, P90
[8]  
Kawashima Makoto, 1992, Journal of Dermatology (Tokyo), V19, P707
[9]  
LUTZNER MA, 1978, B CANCER, V65, P169
[10]  
Lutzner MA, 1984, J INVEST DERMATOL, V83, p18s